FOXP3 Is an X-Linked Breast Cancer Suppressor Gene and an Important of the HER-2/ErbB2 Oncogene

被引：6
|
作者：
Zuo, Tao
Wang, Lizhong
Morrison, Carl
Chang, Xing
Zhang, Huiming
Li, Weiquan
Liu, Yan
Wang, Yin
Liu, Xingluo
Chan, Michael W. Y.
Liu, Jin-Qing
Love, Richard
Liu, Chang-Gong
Godfrey, Virginia
Shen, Rulong
Huang, Tim H-M
Yang, Tianyu
Park, Bae Keun
Wang, Cun-Yu
Zheng, Pan
Liu, Yang
机构：
来源：
CELL | 2021年 / 184卷 / 26期
关键词：
D O I：
10.1016/j.cell.2021.11.030
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：1275 / 1275
页数：1
相关论文
共 50 条
  • [41] Tucatinib HER2 (ErbB2) inhibitor Treatment of breast and colorectal cancer
    Patil, T.
    Shagisultanova, E.
    Borges, V. F.
    DRUGS OF THE FUTURE, 2019, 44 (01) : 11 - 19
  • [42] A modified approach for I-FISH evaluation of ERBB2 (HER-2) gene copy numbers in breast carcinomas: comparison with HER-2/CEP17 ratio system
    Mrhalova, Marcela
    Kodet, Roman
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2007, 133 (05) : 321 - 329
  • [43] COMPLETE - Study the ErbB2 (HER2) - positive Breast cancer.
    Arnheim, Katharina
    Aktas, Bahriye
    ONKOLOGIE, 2010, 33 (04):
  • [44] Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cells
    Xuelian Cui
    Chao Zhang
    Zhifang Xu
    Shuaibin Wang
    Xin Li
    Erica Stringer-Reasor
    Sejong Bae
    Leiping Zeng
    Dehua Zhao
    Runhua Liu
    Lei S. Qi
    Lizhong Wang
    Molecular Cancer, 21
  • [45] Dual CRISPR interference and activation for targeted reactivation of X-linked endogenous FOXP3 in human breast cancer cells
    Cui, Xuelian
    Zhang, Chao
    Xu, Zhifang
    Wang, Shuaibin
    Li, Xin
    Stringer-Reasor, Erica
    Bae, Sejong
    Zeng, Leiping
    Zhao, Dehua
    Liu, Runhua
    Qi, Lei S.
    Wang, Lizhong
    MOLECULAR CANCER, 2022, 21 (01)
  • [46] HER-2 NEU ONCOGENE PROTEIN AND PROGNOSIS IN BREAST-CANCER
    TANDON, AK
    CLARK, GM
    CHAMNESS, GC
    ULLRICH, A
    MCGUIRE, WL
    JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (08) : 1120 - 1128
  • [47] Comparative assays for the HER-2/neu oncogene status in breast cancer
    Vera-Román, JM
    Rubio-Martínez, LA
    ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE, 2004, 128 (06) : 627 - 633
  • [48] Inhibition of fatty acid synthase by amentoflavone suppresses HER2/neu (erbB2) oncogene expression in breast cancer cells
    Chang, E.
    Lee, J.
    Lee, M.
    Cha, E.
    Sul, J.
    Byun, W.
    EJC SUPPLEMENTS, 2010, 8 (03): : 178 - 178
  • [49] HER-2/neu (c-erbB-2) Expression Assessment in Breast Cancer
    Ioanid, N.
    Anton, E.
    Socolov, Demetra
    GINECO RO, 2009, 5 (01): : 43 - 47
  • [50] Amplification of HER-2/neu (erbB2) gene expression in gallbladder (GBC) and in bile duct cancer (BDC) (biliary tract cancer, BTC).
    Kawamoto, T.
    Thomas, M.
    Tarco, E.
    Trivedi, S.
    Wistuba, I.
    Krishnamurthy, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 181S - 181S
12345